We at Greffex believe that genetic approaches will fundamentally change the future of medicine. Information derived from the Human Genome Project will allow the development of novel therapeutic approaches whose implementations will hinge on the availability of an optimized gene delivery system. Numerous different gene transfer system have been investigated many of which were built on different naturally occurring viruses.
Greffex was of the opinion that engineered adenoviruses could form the ideal vehicle to deliver genetic material. They would be safe, stable and “clean”. Earlier iterations of such vectors carried numerous viral genes required for efficient production. These genes had the ability to alter normal cellular behavior and to attract vigorous immune responses. To remove all viral genes and thus prevent their interference, helper viruses originally had to be employed to allow packaging of the therapeutic vector. However contamination of these fully deleted helper dependent adenoviral vectors hamper their introduction into the clinic.
To avoid regulatory issues, we designed a novel adenoviral architecture that allowed the manufacture of fully deleted vectors without the use of a helper virus. With the development of this GREVAX™ Universal Platform, we overcame two obstacles: interference by viral genes and contamination by helper viruses.
The Engineered Veto© Technology
Presently immune suppressive therapies are general rather than specific. We at Greffex searched for an alternative approach that allowed a selective inhibition of immune functions. The origins of our immune suppression technology can be traced to the observation that under certain conditions, T cells confronted by a foreign tissue can be driven to commit suicide, instead of launching an attack. Research on this immune inhibitory effect led us to the development of a tissue engineering approach to organ transplantation.
Our engineered veto© technology uses a GREVAX™ vector to deliver the immune inhibitory CD8™ gene to different transplants. The major advantage of this approach is its ability selectively to inhibit recipients’ immune responses once the tissue has been transplanted. In contrast to present general immune suppression therapies presently used to protect a transplant, normal protective immunity is maintained and recipients are not threatened by infectious diseases.
We have been adapting engineered veto© to “conventional” gene therapy specifically to prevent the immune system from interfering with the therapeutic effect.
The Greffex Protein Production System
Biological products, such as therapeutic proteins, have become an important factor in modern medicine. We at Greffex have adapted viral protein synthesis process to a novel protein production process that allows a more efficient production of protein therapeutics.